SEC Form 4 · accession 0001193125-26-264022
Dyne Therapeutics, Inc. · DYN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jason P Rhodes
Director
Period of report
Jun 5, 2026
Accepted (ET)
Jun 9, 2026 · 5:13 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001818794
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock option (right to buy)F2,F1 | $17.04 | Jun 5, 2026 | A | 35,152 | A | — | Jun 4, 2036 | Common Stock | 35,152 | 35,152 | D |
Explanation of responses
- F1This option was granted on June 5, 2026. The shares underlying the option are scheduled to vest in full on the earlier of (i) June 5, 2027 or (ii) the date of the Issuer's 2027 Annual Meeting of Stockholders, subject to continued service.
- F2The Reporting Person is a member of Atlas Venture Associates XI, LLC and is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the option to Atlas Venture Life Science Advisors, LLC. As such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any.